Pharmageek
Demographie In den bisherigen Blogposts haben wir die räumliche Verteilung der Spender:innen und die gespendeten Schrittzahlen und Pulsraten beleuchtet. In diesem Blogpost beschäftigen wir uns nun eingehender mit der Demographie der Spender:innen. Hierzu gehören die Informationen zu Alter, Geschlecht, Größe, und Gewicht, die Nutzer:innen in der App angeben können.
Einige Spender:innen (etwa 10%) haben neben ihren täglichen Ruhepuls- und Schrittanzahldaten auch freiwillig Informationen zu Alter, Geschlecht, Größe und Gewicht angegeben.
Lire l'article complet sur : corona-datenspende.de
This cohort study examines the duration and variation of recovery among COVID-19–positive verses COVID-19–negative individuals.
Lire l'article complet sur : jamanetwork.com
Datenspende 2.0 is finally here. Since mid-October you can answer short questionnaires in the app to help us to substantially improve our understanding of the donated vital data in relation to COVID-19. More than 12,000 people have already taken part and entrusted us with this information. For this we would like to express a heartfelt thank you right away.
For instance, in the ‘Tests, Symptoms & Life Situation’ questionnaire, we ask donors about the approximate time and result of their first PCR test.
Lire l'article complet sur : corona-datenspende.de
The European Medicines Agency (EMA) has approved Pfizer and BioNTech’s COVID-19 vaccine Comirnaty for children between the ages of five and 11, as EU countries struggle to cope with rising infection rates.
The EU regulator said that the under-12s should get a lower dose of the vaccine – 10 mcg rather than 30 mcg – given as two intramuscular injections three weeks part. The US approved Comirnaty for this age group last month.
So far the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) hasn’t delivered its verdict on the use of Comirnaty in younger children.
However, it has been reported that the UK government is already planning to extend its vaccination programme to the five to 11 age group next year – subject to approval from the Joint Committee on Vaccines and Immunisation (JCVI).
Lire l'article complet sur : pharmaphorum.com